ArticleJournal of diabetes science and technology2022
Glycemic Variability Assessment with a 14-Day Continuous Glucose Monitoring System: When and How Long to Measure MAGE (Mean Amplitude of Glucose Excursion) for Optimal Reliability?
Article in Journal of diabetes science and technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2022Pooled it
- The Evolving Landscape of Continuous Glucose Monitoring Metrics in Type 1 Diabetes: Narrative Literature Review.JMIR diabetes · 2026Review
- Continuous Glucose Monitoring Data Compression Using Peak-Nadir Encoding in Diabetes: Method Development and Evaluation.JMIR biomedical engineering · 2026Article
- Effect of a homemade diet compared to a commercial diet on glycaemic variability and glycaemic control assessed by continuous glucose monitoring system in diabetic dogs: a randomised crossover study.The Journal of small animal practice · 2026Article
- Mapping Lifestyle Factors in Blood Glucose Variability in Adolescents With Type 1 Diabetes Mellitus: A Pilot Study.Pediatric diabetes · 2026Article
- Nonlinear relationship between mean amplitude of glycemic excursion and mortality in critically ill stroke patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- The Impact of Glycaemic Variability on Vascular Dysfunction in Diabetes.Biomolecules · 2025Review
- Analysis of the correlation between glycemic variability indices and disease severity as well as inflammatory status in patients with type 2 diabetes mellitus and periodontitis.Clinical oral investigations · 2025Article
- Clinical relevance of short-term glycemic variability in children and adolescents with type 1 diabetes: a narrative review.Translational pediatrics · 2024Review
- Current landscape and comprehensive management of glycemic variability in diabetic retinopathy.Journal of translational medicine · 2024Review
- Enhancement of Ambulatory Glucose Profile for Decision Assistance and Treatment Adjustments.Diagnostics (Basel, Switzerland) · 2024Article
- How to Measure Glycemic Variability? A Literature Review.Medicina (Kaunas, Lithuania) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mean amplitude of glucose excursion (MAGE) is considered as the "gold standard" for assessing the short-term within-day glycemic variability (GV), which is an important component of overall glycemic control. A 14-day continuous glucose monitoring system is now widely used and allows easier assessment of GV. However, it is still unknown whether MAGE, usually calculated on a 48-hour period is identical whatever the time during the 14-day lifespan of the sensor and whether a longer time period might give additional information. We evaluated in 68 patients with type 1 diabetes, MAGE during three 2-day periods (day1-day3; day6-day8; day11-day13) and during periods of 3 days and 4 days. MAGE calculated at the three 2-day periods were identical and not different from MAGE of the 3-day or 4-day periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.